Lantus SoloStar is a prefilled, disposable insulin pen that delivers insulin glargine, a long-acting insulin analog used to manage blood sugar in people with type 1 and type 2 diabetes. The “SoloStar” part of the name refers to the pen device itself, while “Lantus” is the brand name for insulin glargine at a concentration of 100 units per milliliter. It was the first once-daily basal insulin analog to reach clinical practice, and it remains one of the most widely prescribed insulins in the world.
What Insulin Glargine Actually Does in Your Body
Insulin glargine is designed to mimic the low, steady background insulin your pancreas would normally release between meals and overnight. It is not meant to cover the blood sugar spike after eating; that job falls to rapid-acting mealtime insulins. What makes glargine different from older basal insulins like NPH is its absorption speed. In a study tracking how quickly injected insulin left the injection site in people with type 2 diabetes, glargine was absorbed roughly two to three times more slowly than NPH insulin, with half the dose still lingering under the skin at about 26 hours compared to around 13 hours for NPH.1PubMed. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes That slow, drawn-out release is what gives glargine its relatively flat activity profile over a full day, without the pronounced peak that NPH tends to produce.
This flatter profile matters because peaks and valleys in insulin activity are what set the stage for unexpected blood sugar drops, especially at night. Clinical trials consistently show that once-daily insulin glargine achieves blood sugar control comparable to NPH insulin given once or twice a day, but with fewer episodes of hypoglycemia, particularly the overnight kind.2International Journal of Clinical Practice. INSULIN GLARGINE (LANTUS®) That trade-off, similar control with less risk of dangerous lows, is the central reason glargine became so popular after its approval.
Who Lantus SoloStar Is Prescribed For
Lantus is approved for adults and children with type 1 diabetes and for adults with type 2 diabetes. In type 1 diabetes, the pancreas produces little to no insulin at all, so glargine serves as the essential background insulin while rapid-acting doses cover meals. In type 2 diabetes, the body still makes some insulin but can’t use it efficiently, and many people eventually need injected basal insulin when oral medications and lifestyle changes aren’t enough to keep blood sugar in range.
Evidence supports the idea that glargine’s pharmacokinetics translate into meaningful improvements in glycemic control with a lower risk of hypoglycemia across both patient populations.3PubMed Central. Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes In practice, many people with type 2 diabetes start on Lantus alone, sometimes alongside metformin or other oral drugs, while people with type 1 diabetes almost always use it alongside a rapid-acting insulin at mealtimes in what’s called a basal-bolus regimen.
The Pen Itself and Why It Matters
The SoloStar pen is a gray, disposable, prefilled device about the size of a thick marker. You dial your dose using a numbered window on the pen, attach a pen needle (sold separately), and press the injection button. The pen holds 300 units of insulin glargine total, and you dial doses in one-unit increments up to 80 units per injection.
Pen design may sound like a minor detail, but it has real consequences for people who inject insulin every day. In a head-to-head comparison with other disposable pens, a significantly larger share of patients correctly prepared and performed an injection with the SoloStar on the first try. When asked about preference, over half chose the SoloStar over competing pens.4PubMed. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen Those results held regardless of age, previous pen experience, or whether the person had vision or dexterity problems, which is relevant because diabetes disproportionately affects older adults who may struggle with fine motor tasks.
The injection force required to push the plunger is another practical consideration. Mechanical testing shows that the SoloStar pen requires significantly less thumb force to deliver a dose than comparable pens.5PubMed. Dose accuracy and injection force dynamics of a novel disposable insulin pen For someone injecting daily, especially someone with arthritis or reduced hand strength, lower force translates to a more comfortable and consistent experience.
How to Start and Adjust Your Dose
Most people begin Lantus at a conservative dose, typically around 10 units per day or a weight-based starting point of about 0.2 units per kilogram per day.6Clinical Diabetes. Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers From there, the dose is titrated upward gradually, usually every two to three days, based on fasting blood sugar readings. This slow ramp-up minimizes the risk of hypoglycemia while you and your prescriber find the right dose.
Lantus is injected once daily, at the same time each day. The timing itself, morning versus bedtime, doesn’t appear to make a large clinical difference, though many people inject at bedtime so the insulin covers overnight fasting. You inject it subcutaneously, meaning just under the skin, typically in the abdomen, thigh, or upper arm. Rotating your injection site within the same general area helps avoid lumps of fatty tissue (lipohypertrophy) that can form with repeated injections in the same spot and can interfere with insulin absorption.
A common question is whether you can mix Lantus with other insulins in the same syringe. You cannot. Insulin glargine’s formulation is acidic, and mixing it with other insulin products can alter its absorption characteristics, potentially eliminating the long, steady profile that makes it work as a basal insulin. If you’re on both Lantus and a mealtime insulin, they need to be separate injections.
Side Effects You’re Likely to Encounter
Hypoglycemia, low blood sugar, is the most common side effect of any insulin and Lantus is no exception. Symptoms include shakiness, sweating, confusion, a racing heart, and irritability. Severe episodes can lead to loss of consciousness or seizures if untreated. While glargine’s flat profile does reduce the frequency of hypoglycemia compared to older basal insulins like NPH, the risk never disappears entirely. Skipping meals, exercising more than usual, or injecting too much insulin all raise the odds.
Injection site reactions are another common but usually minor issue. Redness, itching, or mild swelling at the injection site generally resolve on their own and tend to diminish over time. Rarely, people develop allergic reactions such as a rash over a wider area, though true systemic allergic reactions to insulin glargine are uncommon.
Weight gain is worth mentioning because it catches many people off guard. Insulin is an anabolic hormone, meaning it promotes the storage of glucose as fat. When blood sugar improves with insulin therapy, the body retains calories that were previously being lost in the urine. This effect is not unique to Lantus; it happens with virtually all insulin products. Typical weight gain in clinical trials is a few pounds over the first months of therapy. For people with type 2 diabetes already concerned about weight, this can be a source of frustration, though the metabolic benefits of blood sugar control generally outweigh the modest increase.
Rare but Serious Risks
Severe hypoglycemia is the most dangerous acute risk. It can occur when too much insulin is given relative to food intake or activity level. In extreme cases, insulin-induced hypoglycemia can trigger dangerously low potassium levels (hypokalemia), which in turn can cause heart rhythm disturbances. Case reports have documented cardiac arrest in the setting of insulin-induced hypokalemia, though these events are exceedingly rare and typically involve extreme circumstances such as a very high starting blood sugar treated aggressively in a hospital setting.
Another rare concern is lipodystrophy at the injection site, where repeated injections in the same location cause either a buildup or loss of fatty tissue. The practical problem here is that lipodystrophy changes how insulin is absorbed from that spot, making your dose less predictable. Rotating injection sites as recommended largely prevents this.
Storing Your Pen Correctly
Insulin is a protein, and like most proteins, it degrades when exposed to heat, freezing temperatures, or direct sunlight. Before you start using a Lantus SoloStar pen, it should be stored in the refrigerator at roughly 36°F to 46°F (2°C to 8°C). Once you’ve started using a pen, it can be kept at room temperature (up to about 86°F or 30°C) for 28 days, after which it should be discarded even if insulin remains inside.
Real-world storage conditions frequently fall short of these recommendations. Research on insulin storage habits has found that many people inadvertently expose their insulin to temperature extremes, whether from a too-cold spot in the back of the refrigerator or a hot car dashboard in summer.7PubMed Central. Insulin Storage: A Critical Reappraisal Degraded insulin doesn’t necessarily look different in the pen, so you might not realize your dose is less potent. If your blood sugar readings start drifting higher for no clear reason and you’ve been storing your pen in a questionable spot, a new pen is a reasonable first step before adjusting your dose.
Using Lantus During Pregnancy
Diabetes management during pregnancy is critical because uncontrolled blood sugar increases the risk of complications for both the mother and the baby. A natural question for anyone on Lantus who becomes pregnant, or who is planning pregnancy, is whether insulin glargine is safe for the developing fetus.
An important piece of evidence comes from a placental transfer study that tested whether insulin glargine crosses from the maternal to the fetal side. At therapeutic concentrations, no detectable insulin glargine was found in the fetal circuit. Even at concentrations hundreds of times higher than what a patient would normally have, the transfer rate remained extremely low.8PubMed Central. Insulin glargine safety in pregnancy: a transplacental transfer study This is reassuring, though decisions about insulin therapy in pregnancy should always be made with an endocrinologist or maternal-fetal medicine specialist, because insulin needs change substantially as pregnancy progresses.
Pens vs. Vials and What the Switch Means for Adherence
Insulin glargine is also available in traditional vials for use with syringes. The SoloStar pen is more convenient and discreet, but it also appears to make a measurable difference in whether people actually take their insulin consistently. A real-world study tracked people with type 2 diabetes who switched from a glargine vial-and-syringe setup to the pen. After one year, treatment persistence was significantly higher among the pen users compared to those who stayed on vials, with about two-thirds of pen users still on therapy versus roughly half of the vial group.9PubMed. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus
Separate survey data from Europe and Canada found that the vast majority of patients rated the SoloStar pen as easier to use than their previous pen, with 98% saying they planned to continue with it.10PubMed Central. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes Satisfaction numbers that high suggest the pen removes enough friction from the daily injection routine to keep people on track. That matters because missed basal insulin doses lead directly to uncontrolled blood sugar, and adherence gaps are one of the most common reasons people with diabetes don’t meet their glycemic targets.
Biosimilar Options and Cost Considerations
The cost of Lantus has been a persistent concern. In 2021, the FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar to Lantus.11PubMed. Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States An interchangeable biosimilar can be substituted at the pharmacy without requiring a new prescription from your doctor, much like a generic drug, though the regulatory pathway for biosimilars is different because insulin is a biologic product rather than a simple chemical molecule.
The approval of biosimilar insulin products was based on detailed comparative analyses confirming that the biosimilar has the same pharmacokinetic and pharmacodynamic profile as the reference product.12PubMed. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products In practical terms, this means Semglee works the same way, at the same speed, and at the same dose as Lantus. Other biosimilar glargine products, such as Basaglar, have also been on the market for several years, though Basaglar was approved through a slightly different regulatory pathway and is not technically labeled as “interchangeable” in the same legal sense. For patients, the difference between these products is largely about cost and insurance coverage rather than clinical effect.
If you’re paying out of pocket or facing a high copay for Lantus, asking your pharmacist or prescriber about biosimilar alternatives is a reasonable first step. Many insurance plans now prefer biosimilars on their formularies, and the price difference can be substantial.
The Environmental Footprint of Disposable Pens
Disposable insulin pens create a waste problem that rarely gets discussed at the doctor’s office. Each SoloStar pen is used for days to weeks and then discarded, and millions of these devices are used worldwide every day. The pens themselves are made of plastic, and the used pen needles are classified as sharps waste requiring special disposal. Together with packaging, this adds up to a considerable volume of medical plastic waste.13PubMed Central. Diabetes Technology and Waste: A Complex Story
Some regions offer sharps disposal programs through pharmacies or mail-back services, but there is no widely available recycling stream for used insulin pens. Reusable pen platforms exist for some insulin products, where you load a cartridge and replace only that when it’s empty, but Lantus SoloStar is not available in a reusable format. For people who are environmentally conscious and weighing pen versus vial, it’s worth knowing that vial-and-syringe setups generate somewhat less plastic per unit of insulin, though they come with the adherence trade-off discussed earlier. The modified SoloStar pen designed for the higher-concentration glargine formulation (300 units per milliliter) does deliver the same number of units in a smaller volume, which means fewer pen bodies consumed over time for people on high doses.14PubMed Central. Accuracy and Injection Force of the Gla-300 Injection Device Compared With Other Commercialized Disposable Insulin Pens But broadly speaking, the diabetes device industry has been slow to address its environmental impact, and disposable pens remain the standard.